📣 VC round data is live. Check it out!

Prelude Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Prelude Therapeutics and similar public comparables like IMBiologics, Santhera Pharma, Zentalis Pharma, Oryzon Genomics and more.

Prelude Therapeutics Overview

About Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.


Founded

2016

HQ

United States

Employees

131

Financials (LTM)

Revenue: $19M
EBITDA: ($109M)

EV

$216M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Prelude Therapeutics Financials

Prelude Therapeutics reported last 12-month revenue of $19M and negative EBITDA of ($109M).

In the same LTM period, Prelude Therapeutics generated ($109M) in EBITDA losses and had net loss of ($83M).

Revenue (LTM)


Prelude Therapeutics P&L

In the most recent fiscal year, Prelude Therapeutics reported revenue of $12M and EBITDA of ($103M).

Prelude Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (847%) and net margin of (820%).

See analyst estimates for Prelude Therapeutics
LTMLast FY202320242025202620272028
Revenue$19M$12M-$7M$12M
EBITDA($109M)($103M)($131M)($138M)($103M)
EBITDA Margin(572%)(847%)-(1971%)(847%)
EBIT Margin(459%)(861%)-(1996%)(861%)
Net Profit($83M)($99M)($122M)($127M)($99M)
Net Margin(437%)(820%)-(1817%)(820%)

Financial data powered by Morningstar, Inc.

Prelude Therapeutics Stock Performance

Prelude Therapeutics has current market cap of $280M, and enterprise value of $216M.

Market Cap Evolution


Prelude Therapeutics' stock price is $3.51.

Prelude Therapeutics share price decreased by 10.2% in the last 30 days, and increased by 333.7% in the last year.

Prelude Therapeutics has an EPS (earnings per share) of $-1.25.

See more trading valuation data for Prelude Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$216M$280M-8.1%-10.2%2.7%333.7%$-1.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Prelude Therapeutics Valuation Multiples

Prelude Therapeutics trades at 11.3x EV/Revenue multiple, and (2.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Prelude Therapeutics

EV / Revenue (LTM)


Prelude Therapeutics Financial Valuation Multiples

As of June 4, 2026, Prelude Therapeutics has market cap of $280M and EV of $216M.

Prelude Therapeutics has a P/E ratio of (3.4x).

LTMLast FY202320242025202620272028
EV/Revenue11.3x17.8x-30.8x17.8x
EV/EBITDA(2.0x)(2.1x)(1.6x)(1.6x)(2.1x)
EV/EBIT(2.5x)(2.1x)(1.6x)(1.5x)(2.1x)
P/E(3.4x)(2.8x)(2.3x)(2.2x)(2.8x)
EV/FCF3.7x2.1x(2.0x)(2.1x)(3.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Prelude Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Prelude Therapeutics Margins & Growth Rates

Prelude Therapeutics grew revenue by 134% and EBITDA by 11% in the last fiscal year.

In the most recent fiscal year, Prelude Therapeutics reported EBITDA margin of (847%) and net margin of (820%).

See estimated margins and future growth rates for Prelude Therapeutics

Prelude Therapeutics Margins

Last FY202420252026202720282029
EBITDA Margin(847%)(1971%)(847%)(402%)
EBIT Margin(861%)(1996%)(861%)(223%)
Net Margin(820%)(1817%)(820%)(213%)
FCF Margin831%(1481%)(464%)0%

Prelude Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth134%-73%134%
EBITDA Growth11%5%(25%)11%
EBIT Growth(39%)6%(25%)(39%)
Net Profit Growth(39%)4%(22%)(39%)
FCF Growth(100%)(6%)(46%)(100%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Prelude Therapeutics Operational KPIs

Prelude Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.

Prelude Therapeutics' Rule of 40 is (268%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Prelude Therapeutics' Rule of X is (66%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Prelude Therapeutics
LTMLast FY20242025202620272028
Rule of 40(467%)(268%)--
Bessemer Rule of X(310%)(66%)--
Revenue per Employee-$0.1M--
Opex per Employee-$0.9M--
G&A Expenses to Revenue114%185%410%185%
R&D Expenses to Revenue429%777%1686%777%
Opex to Revenue-961%2096%961%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Prelude Therapeutics Competitors

Prelude Therapeutics competitors include IMBiologics, Santhera Pharma, Zentalis Pharma, Oryzon Genomics, Immuneering, Panacea Biotec, Eledon Pharmaceuticals, Organogenesis, Surrozen and SAB Bio.

Most Prelude Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
IMBiologics-27.6x--
Santhera Pharma3.2x2.9x(7.8x)(11.9x)
Zentalis Pharma--(0.7x)(0.7x)
Oryzon Genomics-78.6x(44.4x)(25.5x)
Immuneering--(2.1x)-
Panacea Biotec3.9x-79.5x-
Eledon Pharmaceuticals--(2.0x)-
Organogenesis0.7x0.9x4.1x17.7x

This data is available for Pro users. Sign up to see all Prelude Therapeutics competitors and their valuation data.

Start Free Trial

Prelude Therapeutics VC Funding History

Before going public, Prelude Therapeutics raised $122M in total equity funding, across 3 rounds.


Prelude Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-20Series CFidelity; OrbiMed$50M-Prelude Therapeutics is a Wilmington-based clinical-stage biopharmaceutical oncology company focused on precision medicine and the discovery and development of small molecule therapies targeting genetically defined cancer drivers. Founded in 2016 by Kris Vaddi, Ph.D., the company designs therapeutics to address key drivers of cancer cell growth, survival, and resistance to existing treatments. The company's pipeline includes programs being evaluated in clinical trials for bone marrow-related malignancies and solid tumors including glioblastoma multiforme affecting the brain or spine. In August 2020, Prelude announced a $50 million Series C funding round led by OrbiMed Advisors and Fidelity Management & Research Company. The financing was intended to accelerate pipeline development and advance the company toward clinical milestones. Prior to this round, Prelude had raised $60 million in Series B funding in 2019. The company went public approximately one month after the Series C announcement, completing an IPO on September 25, 2020 at $19 per share, raising approximately $158 million gross proceeds with Morgan Stanley, Goldman Sachs, and Bank of America Securities as underwriters. At IPO, founder and CEO Kris Vaddi held approximately 12.4% of the company. As a clinical-stage company at the time of the Series C round, Prelude had not yet generated meaningful revenue and was operating at a net loss, having reported losses of $27.6 million for the full year 2019 and $20.9 million for the first half of 2020.
Jun-19Series BOrbiMed$60M-Prelude Therapeutics Inc., a Wilmington, Delaware-based biopharmaceutical company, raised $60 million in a Series B funding round on June 12, 2019, led by OrbiMed Advisors and one undisclosed institutional investor. The funds were intended to advance its lead PRMT5 inhibitor program through clinical proof-of-concept for solid tumors and blood cancers. OrbiMed had previously participated in Prelude's $5 million seed round in July 2016 and $30 million Series A in October 2017. The company focuses on oncology therapeutics targeting key drivers of cancer cell growth, survival, and resistance. At the time, Prelude was developing small-molecule inhibitors, with its PRMT5 program in preclinical stages aiming for clinical entry. Prelude later raised a $50 million Series C in an unspecified later date in 2019 or beyond, again involving OrbiMed alongside Fidelity Management & Research Company, to further pipeline development including clinical trials for bone marrow malignancies and solid tumors like glioblastoma multiforme. The company originated from the Delaware Innovation Space accelerator in 2016.
Oct-17Series A-$12M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Prelude Therapeutics

When was Prelude Therapeutics founded?Prelude Therapeutics was founded in 2016.
Where is Prelude Therapeutics headquartered?Prelude Therapeutics is headquartered in United States.
How many employees does Prelude Therapeutics have?As of today, Prelude Therapeutics has over 131 employees.
Who is the CEO of Prelude Therapeutics?Prelude Therapeutics' CEO is Krishna Vaddi.
Is Prelude Therapeutics publicly listed?Yes, Prelude Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Prelude Therapeutics?Prelude Therapeutics trades under PRLD ticker.
When did Prelude Therapeutics go public?Prelude Therapeutics went public in 2020.
Who are competitors of Prelude Therapeutics?Prelude Therapeutics main competitors include IMBiologics, Santhera Pharma, Zentalis Pharma, Oryzon Genomics, Immuneering, Panacea Biotec, Eledon Pharmaceuticals, Organogenesis, Surrozen, SAB Bio.
What is the current market cap of Prelude Therapeutics?Prelude Therapeutics' current market cap is $280M.
What is the current revenue of Prelude Therapeutics?Prelude Therapeutics' last 12 months revenue is $19M.
What is the current revenue growth of Prelude Therapeutics?Prelude Therapeutics revenue growth (NTM/LTM) is 105%.
What is the current EV/Revenue multiple of Prelude Therapeutics?Current revenue multiple of Prelude Therapeutics is 11.3x.
Is Prelude Therapeutics profitable?No, Prelude Therapeutics is not profitable.
What is the current EBITDA of Prelude Therapeutics?Prelude Therapeutics has negative EBITDA and is not profitable.
What is Prelude Therapeutics' EBITDA margin?Prelude Therapeutics' last 12 months EBITDA margin is (572%).
What is the current EV/EBITDA multiple of Prelude Therapeutics?Current EBITDA multiple of Prelude Therapeutics is (2.0x).
What is the current FCF of Prelude Therapeutics?Prelude Therapeutics' last 12 months FCF is $58M.
What is Prelude Therapeutics' FCF margin?Prelude Therapeutics' last 12 months FCF margin is 307%.
What is the current EV/FCF multiple of Prelude Therapeutics?Current FCF multiple of Prelude Therapeutics is 3.7x.
How many companies Prelude Therapeutics has acquired to date?Prelude Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Prelude Therapeutics has invested to date?Prelude Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Prelude Therapeutics

Lists including Prelude Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial